Braidwell LP is a Stamford, Connecticut-based investment firm focused on life sciences and healthcare, investing across public equities, private markets, and structured capital. Founded in 2021 by Alex Karnal and Brian Kreiter, the firm launched with approximately $3.5 billion and operates a flagship hedge fund, a credit platform, and an early-stage incubator (Braidwell Labs).
69% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deal in the last 12 months vs 6 prior). Average disclosed round size is $164.3M (across 15 rounds with reported amounts).
Portfolio
15
Fund Size
$3.5B
Top Stage
Series C
Last 12 Mo
1
Team
Alex Karnal
Chief Investment Officer, Partner, Co-Founder
Brian Kreiter
Chief Executive Officer, Partner, Co-Founder
Portfolio Breakdown
Stage Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Encoded Therapeutics | Series F | $275M | Sep 2026 |
| Encoded Therapeutics | Series F | $275M | Jan 2026 |
| EEncoded | Series F | $275M | Jan 2026 |
 Crescent Biopharma | Growth | $200M | Jun 2025 |
 Surrozen | Series D | $175M | Mar 2025 |
| PPerceive Pharma | Series A | $15M | Feb 2025 |
 Perceive Bio | Series A | $15M | Feb 2025 |
 Timberlyne Therapeutics | Series A | $180M | Jan 2025 |
 Elektrofi | Series C | $112.3M | Oct 2024 |
 Bicara Therapeutics | Series C | $165M | Dec 2023 |
| BBicara | Series C | $165M | Dec 2023 |
 Bicara Therapeutics | Series C | $165M | Dec 2023 |
 Caris Life Sciences | Unknown | — | Jan 2023 |
 Jade Biosciences | Unknown | $95M | — |
 Oruka Therapeutics | Growth | $275M | — |
| PPerceive Biotherapeutics | Series B | $78M | — |
Top Co-Investors
Last updated: 20 October 2026